Literature DB >> 28537820

Photodynamic Diagnosis and Narrow-Band Imaging in the Management of Bladder Cancer: A Review.

Piotr Kutwin1, Tomasz Konecki1, Marcin Cichocki1, Piotr Falkowski1, Zbigniew Jabłonowski1.   

Abstract

BACKGROUND: Bladder cancer is the most common malignancy of the urinary tract. Its proper diagnosis and efficient treatment is still considered a challenge in urology today. White light cystoscopy is a gold standard for the diagnosis, follow-up, and endoscopic treatment of bladder cancer. To improve the efficacy of bladder cancer management, photodynamic diagnosis and narrow-band imaging have been introduced to the urological armamentarium. OBJECTIVE AND METHODS: The article presents the current state of knowledge of technical solutions that are intended to improve the diagnosis and management of bladder cancer. A nonsystemic review of relevant PubMed literature was performed.
RESULTS: Photodynamic diagnosis and narrow-band imaging improve the detection of bladder cancer and decrease recurrence rates of bladder tumors.
CONCLUSIONS: Although the high cost of the equipment may limit its introduction to everyday use, it is a cost-effective method of bladder cancer management for long-term follow-up.

Entities:  

Keywords:  NBI; PDD; bladder cancer; narrow-band imaging; photodynamic diagnosis; review

Mesh:

Year:  2017        PMID: 28537820     DOI: 10.1089/pho.2016.4217

Source DB:  PubMed          Journal:  Photomed Laser Surg        ISSN: 1549-5418            Impact factor:   2.796


  9 in total

1.  MiR-192-5p suppresses the growth of bladder cancer cells via targeting Yin Yang 1.

Authors:  Decai Ji; Lining Jiang; Yingjie Li
Journal:  Hum Cell       Date:  2018-03-13       Impact factor: 4.174

2.  Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.

Authors:  Filippo Pederzoli; Belkiss Murati Amador; Iryna Samarska; Kara A Lombardo; Max Kates; Trinity J Bivalacqua; Andres Matoso
Journal:  Hum Pathol       Date:  2019-05-06       Impact factor: 3.466

3.  Significance of 5-Aminolevulinic Acid-mediated Photodynamic Diagnosis Following Standard Transurethral Resection in Non-muscle Invasive Bladder Cancer.

Authors:  Kyohei Watanabe; Keita Tamura; Yuto Matsushita; Hiromitsu Watanabe; Daisuke Motoyama; Toshiki Ito; Takayuki Sugiyama; Atsushi Otsuka; Hideaki Miyake
Journal:  Cancer Diagn Progn       Date:  2021-07-03

Review 4.  Advances in Diagnosis and Therapy for Bladder Cancer.

Authors:  Xinzi Hu; Guangzhi Li; Song Wu
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

5.  Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection.

Authors:  Hiroki Hagimoto; Noriyuki Makita; Yuta Mine; Hidetoshi Kokubun; Shiori Murata; Yohei Abe; Masashi Kubota; Naofumi Tsutsumi; Toshinari Yamasaki; Mutsushi Kawakita
Journal:  BMC Urol       Date:  2021-12-22       Impact factor: 2.264

Review 6.  Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review.

Authors:  Prashant Motiram Mulawkar; Gyanendra Sharma; Ashwin Tamhankar; Utsav Shah; Rickaz Raheem
Journal:  Front Surg       Date:  2022-02-21

Review 7.  Long Non-coding RNA DANCR as an Emerging Therapeutic Target in Human Cancers.

Authors:  Shi-Jia Jin; Ming-Zhu Jin; Bai-Rong Xia; Wei-Lin Jin
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

8.  MPPa-PDT suppresses breast tumor migration/invasion by inhibiting Akt-NF-κB-dependent MMP-9 expression via ROS.

Authors:  Liyi Huang; Haidan Lin; Qing Chen; Lehua Yu; Dingqun Bai
Journal:  BMC Cancer       Date:  2019-11-29       Impact factor: 4.430

9.  Novel Visualization Methods Assisted Transurethral Resection for Bladder Cancer: An Updated Survival-Based Systematic Review and Meta-Analysis.

Authors:  Honglin Li; Yubin Cao; Pingchuan Ma; Zhongkai Ma; Chunjie Li; Wenbin Yang; Lingyun Zhou
Journal:  Front Oncol       Date:  2021-07-13       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.